GliaCure is a pioneer in the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company’s approaches are based on glial targets, a cell type in the brain that has previously been overlooked in drug discovery.
The company has developed a small molecule clinical candidate – GC021109 – for a glial target that has two primary actions downstream of target engagement: the stimulation of phagocytosis and anti-inflammatory actions in which levels of pro-inflammatory cytokines are reduced.
GC021109 is currently being developed primarily as a disease modifying treatment of Alzheimer’s disease; however, its dual phagocytosis and anti-inflammatory actions have the potential to affect other disorders. In addition to its program using GC021109, GliaCure has a pipeline program for the development of therapeutics for astrocytic targets related to additional disorders, such as depression and sleep consolidation.
GliaCure is a virtual drug discovery company, a cutting edge approach in life sciences that allows it to work with expert consultants on an as-needed basis to allow rapid decision-making and to maximize investment. The company has raised approximately $8.5 million to date from private investors.
GliaCure was founded in 2011 and is based on discoveries by its scientific founder, Philip Haydon, Ph.D., of Tufts University and is based in Boston, Massachusetts.